Cancers is a leading peer-reviewed journal published by MDPI, dedicated to advancing the field of oncology and cancer research. Established in 2009 and based in Switzerland, this Open Access journal provides a platform for the rapid dissemination of high-quality research findings, reviews, and clinical studies related to all aspects of cancer biology and treatment. With an impressive impact factor and recognized as Q1 in Oncology and Q2 in Cancer Research for 2023, Cancers strives to foster a collaborative environment among researchers, healthcare professionals, and students seeking to deepen their knowledge and understanding of cancer. The journal’s commitment to accessibility and its broad scope make it an invaluable resource for anyone passionate about combating cancer and improving patient outcomes. For more information and to access its diverse publications, visit the journal’s website.

Gastrointestinal Tumors is a reputable, peer-reviewed journal dedicated to advancing knowledge in the field of gastrointestinal oncology. Published by KARGER, this journal has been a pivotal platform since its transition to Open Access in 2014, ensuring that research findings are accessible to a global audience of researchers, clinicians, and students engaged in this vital area of study. With an emphasis on innovative research, clinical studies, and comprehensive reviews, Gastrointestinal Tumors aims to bridge gaps in knowledge and foster discussions that will inform and enhance clinical practices. The journal's commitment to excellence reflects the rising importance of gastrointestinal health in medical research, making it an essential resource for anyone seeking to stay at the forefront of this rapidly evolving field. Based in Basel, Switzerland, it is positioned within a strong academic community, and continues to influence the landscape of gastrointestinal cancer research.

NEURO-ONCOLOGY, a leading journal published by OXFORD UNIVERSIT PRESS INC, is at the forefront of research in the intersection of neurology and oncology, with contributions spanning from 1999 to 2024. With a recognized impact reflected in its strong ranking, holding Q1 status in Cancer Research, Neurology (Clinical), and Oncology categories, NEURO-ONCOLOGY provides a vital platform for the dissemination of groundbreaking studies and advancements in brain tumor research and treatment. The journal ranks impressively within the 99th percentile in clinical neurology and 96th percentile in oncology, highlighting its significance and influence within the field. Accessible through institutional subscriptions, it serves as a valuable resource for researchers, healthcare professionals, and students seeking to stay informed of the latest developments, therapeutic strategies, and scientific discussions in neuro-oncology.

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, published by Oxford University Press Inc, stands as a pivotal resource for advancing research and knowledge in the domains of neuropathology and experimental neurology. Established in 1942, this esteemed journal has expanded its influence, as evidenced by its Q1 rankings in both Neurology (clinical) and Pathology and Forensic Medicine, along with its strong placement in Cellular and Molecular Neuroscience. With an emphasis on innovative research and clinical practices, it caters to a diverse audience, including researchers and clinicians dedicated to understanding neurological disorders through a multidisciplinary lens. While not open access, this journal provides access to cutting-edge studies that are pivotal in shaping the future of medical science and pathology. Researchers benefit from its rigorous peer-review process, ensuring the publication of high-caliber work that meets the evolving demands of the field.

Journal of Bone Oncology, published by ELSEVIER, is a pivotal open access journal that has been advancing the field of oncology since its inception in 2012. Focused on the intricate relationship between bone-related malignancies and therapeutic advancements, this journal addresses critical issues in bone oncology, including novel treatments, diagnostic methodologies, and translational research. With a commendable impact factor reflecting its scholarly contributions and ranking in the Q2 category of oncology journals (2023), the Journal of Bone Oncology is recognized within the top 67th percentile across Scopus rankings, showcasing its relevance and quality in the medical oncology landscape. Available in open access, the journal promotes widespread dissemination of knowledge, ensuring that researchers, professionals, and students can access groundbreaking research that informs clinical practices and enhances patient outcomes. Located in Germany and targeting a global audience, the journal’s wealth of resources serves as an essential platform for fostering collaboration and innovation in the oncology community.

Brain and Spine is a premier academic journal published by ELSEVIER, dedicated to advancing the fields of neuroscience and neurology. With its unique focus on the complex interactions between brain function and spinal health, this journal serves as an essential resource for researchers, clinicians, and students alike. Though currently lacking an official impact factor, its ranking within Scopus highlights its relevance, placing it in the 25th percentile for neuroscience (miscellaneous) and the 23rd percentile within neurology, indicating that while it is a developing journal, it holds potential for significant contributions to the field. Operating under open-access principles, it aims to disseminate valuable findings widely, ensuring that novel insights into neurological health are accessible to a global audience. Brain and Spine seeks to foster interdisciplinary collaboration and innovation, making it an invaluable platform for those striving to enhance our understanding of the brain and spinal cord's intricate functions and interdependencies.

Molecular Oncology, published by WILEY, is a premier open-access journal that has been at the forefront of cancer research since its inception in 2007. With an impressive impact factor reflective of its outstanding contribution to the field, it holds a prestigious position in the Q1 category across multiple disciplines, including Cancer Research, Genetics, and Molecular Medicine. This journal is essential for researchers and professionals seeking to publish high-quality findings in a rapidly evolving area of study, underscored by its significant Scopus rankings that place it within the top percentiles of Oncology and Molecular Biology. As an open-access journal since 2017, it ensures that vital research is readily available to a global audience, thereby facilitating collaboration and knowledge dissemination among academic and clinical communities. With its commitment to innovative and impactful research, Molecular Oncology continues to be a critical resource for advancing our understanding of cancer biology and treatment.

CLINICAL NEUROLOGY AND NEUROSURGERY, published by Elsevier, is a pivotal journal in the fields of neurology and neurosurgery, recognized for its rigorous peer-review process and commitment to advancing clinical practices. Established in 1974, the journal has become a respected source of innovative research, evidenced by its excellent Scopus rankings—placing it within the top half of journals in both Medicine (Surgery) and the clinical aspect of Neurology. Notably, it has achieved a Q2 ranking in both Medicine (miscellaneous) and Surgery, and Q3 in Neurology (clinical) as of 2023. The journal publishes a wide array of articles focused on the latest findings, clinical practices, and technological advancements that address neurological disorders and surgical interventions. While it does not currently operate under an open-access model, it remains highly accessible to academic institutions and professionals worldwide from its editorial base in the Netherlands. By enabling knowledge-sharing and fostering collaboration among researchers, practitioners, and students, CLINICAL NEUROLOGY AND NEUROSURGERY plays a crucial role in shaping the future of clinical neurology and surgical techniques.

JOURNAL OF CLINICAL NEUROSCIENCE is an esteemed publication dedicated to advancing the field of neurology and related medical disciplines. Published by ELSEVIER SCI LTD, this journal serves as a vital resource for researchers, clinicians, and educators, providing a platform for the dissemination of high-quality research findings since its inception in 1994. With a noteworthy impact factor and ranked within the Q2 and Q3 categories across various medical specialties, including neurology and surgery, the journal positions itself at the forefront of clinical neuroscience. Although it operates under a traditional subscription model, the journal’s commitment to publishing rigorous scientific work ensures that it remains an integral reference for anyone involved in the diagnosis, treatment, and understanding of neurological disorders. Readers can access a diverse array of articles that not only highlight current research trends but also foster the exchange of innovative ideas in clinical practice.

Neurosurgical Focus, an esteemed journal published by the American Association of Neurological Surgeons, stands at the forefront of neurosurgical research and clinical practice. With its ISSN 1092-0684, this peer-reviewed publication has made a significant impact in the fields of Medicine, Neurology, and Surgery, consistently ranking in the top quartile (Q1) across these categories based on the 2023 metrics. The journal, which spans a rich temporal landscape from 2000 to 2024, offers a platform for disseminating vital research findings, insightful reviews, and innovative surgical techniques. While it is not open access, its high Scopus rankings—40th out of 551 in Medicine & Surgery and 97th out of 400 in Neurology—highlight its broader influence and the quality of research it curates. As an essential resource for researchers, clinicians, and students, Neurosurgical Focus is dedicated to advancing the field of neurosurgery and fostering intellectual discourse within the community.